Celldex Therapeutics (CLDX) Liabilities and Shareholders Equity (2010 - 2026)

Celldex Therapeutics' Liabilities and Shareholders Equity history runs 17 years deep, the most recent figure standing at $511.3 million for Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity fell 30.86% year-over-year to $511.3 million in Q1 2026; TTM through Mar 2026 was $2.4 billion, a 23.92% decrease from a year earlier, with the FY2025 full-year figure at $583.0 million, down 26.42% from the prior year.
• Liabilities and Shareholders Equity fell to $511.3 million in Q1 2026 per CLDX's latest filing, from $583.0 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $868.8 million in Q1 2024 and bottomed at $280.3 million in Q3 2023.
• The 5-year median for Liabilities and Shareholders Equity is $511.3 million (2026), against an average of $554.3 million.
• Across the five-year window, Liabilities and Shareholders Equity jumped 193.72% in 2024 and tumbled 30.86% in 2026, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $352.7 million in 2022, then soared by 32.0% to $465.6 million in 2023, then soared by 70.17% to $792.3 million in 2024, then decreased by 26.42% to $583.0 million in 2025, then retreated by 12.3% to $511.3 million in 2026.
• Per Business Quant, the three latest CLDX Liabilities and Shareholders Equity figures stand at $511.3 million (Q1 2026), $583.0 million (Q4 2025), and $648.4 million (Q3 2025).